NewAmsterdam Pharma Management
Management criteria checks 2/4
NewAmsterdam Pharma's CEO is Michael Davidson, appointed in Aug 2020, has a tenure of 5.75 years. total yearly compensation is $13.64M, comprised of 4.7% salary and 95.3% bonuses, including company stock and options. directly owns 0.25% of the company’s shares, worth $10.50M. The average tenure of the management team and the board of directors is 2.9 years and 3.3 years respectively.
Key information
Michael Davidson
Chief executive officer
US$13.6m
Total compensation
| CEO salary percentage | 4.74% |
| CEO tenure | 5.8yrs |
| CEO ownership | 0.3% |
| Management average tenure | 2.9yrs |
| Board average tenure | 3.3yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$213m |
| Dec 31 2025 | US$14m | US$646k | -US$204m |
| Sep 30 2025 | n/a | n/a | -US$221m |
| Jun 30 2025 | n/a | n/a | -US$166m |
| Mar 31 2025 | n/a | n/a | -US$187m |
| Dec 31 2024 | US$6m | US$621k | -US$242m |
| Sep 30 2024 | n/a | n/a | -US$199m |
| Jun 30 2024 | n/a | n/a | -US$229m |
| Mar 31 2024 | n/a | n/a | -US$229m |
| Dec 31 2023 | US$6m | US$569k | -US$177m |
Compensation vs Market: Michael's total compensation ($USD13.64M) is above average for companies of similar size in the US market ($USD7.00M).
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
CEO
Michael Davidson (69 yo)
Dr. Michael Harvey Davidson, M.D., FACC., FNLA, serves as Director at Nanophoria S.R.L. since January 2024. Dr. Davidson is a Co-Founder and Chief Scientific Officer of TROFI NUTRITIONALS, INC. He serves a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Executive Director | 5.8yrs | US$13.64m | 0.25% $ 10.0m | |
| Founder | 6.3yrs | US$4.81m | 0.064% $ 2.5m | |
| Chief Financial Officer | 2.6yrs | US$4.70m | 0.0065% $ 254.4k | |
| Chief Operating Officer | 5.2yrs | US$5.44m | 0.0075% $ 296.5k | |
| Chief Accounting Officer | 2.6yrs | US$2.24m | 0.0020% $ 79.1k | |
| Executive VP & Head of Investor Relations | 3.1yrs | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 1yr | no data | no data | |
| Executive Vice President of Sales Enterprise Operations | 2.7yrs | no data | no data | |
| Chief People Officer | 1.3yrs | no data | no data | |
| Chief Strategy & Business Officer | 2.1yrs | US$3.26m | 0.00094% $ 37.0k | |
| Chief Development Officer | 3.8yrs | no data | no data | |
| Chief Manufacturing Officer | 5.1yrs | no data | no data |
Experienced Management: NAMS's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Executive Director | 3.5yrs | US$13.64m | 0.25% $ 10.0m | |
| Founder | 6.3yrs | US$4.81m | 0.064% $ 2.5m | |
| Independent Non-Executive Director | 3.5yrs | US$673.92k | 0.0020% $ 78.0k | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Chairman of Board of Directors | 2.3yrs | US$693.92k | 0.0020% $ 78.0k | |
| Independent Director | 3.3yrs | US$676.42k | 0.0020% $ 78.0k | |
| Independent Non-Executive Vice Chairman | 1.8yrs | US$663.92k | 0.0020% $ 78.0k | |
| Independent Non-Executive Director | 1.8yrs | US$43.00k | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data |
Experienced Board: NAMS's board of directors are considered experienced (3.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/31 01:52 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NewAmsterdam Pharma Company N.V. is covered by 19 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Steven Seedhouse | Cantor Fitzgerald & Co. |
| Geoffrey Meacham | Citigroup Inc |
| Asad Haider | Goldman Sachs |